SBIR and STTR BAAs and CSOs are released at the same time in separate documents
Anwars office, we carefully select products backed by science and clinical evidence
Completed human trials establishing safety and efficacy would enable consideration for approval pathways
As described earlier, this methodology is grounded in previously published literature and uses publicly available information (for example, the OPAIS database) as well as claims-level data to determine the total number of units of a Part D rebatable drug for which a discount was provided under the 340B Program for the last 3 calendar quarters of the applicable period that begins on October 1, 2025 to implement section 1860D-14B(b)(1)(B) of the Act
Their compounding status under federal law is still being determined: removal from the Category 2 restricted list takes effect April 23, 2026, and the FDAs Pharmacy Compounding Advisory Committee will review whether to officially clear any of them at its July 23-24, 2026 meeting
Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland
